This protocol applies to hyperprolactinemia caused by a malignant prolactinoma — a rare, aggressive form defined by metastatic spread within or outside the central nervous system. The clinical priority is controlling both elevated prolactin and ongoing tumor progression.
A malignant prolactinoma is defined as one that exhibits metastatic spread within or outside the central nervous system. This distinguishes it from typical invasive adenomas and demands a distinct management strategy.
Reduction in serum prolactin levels and control of tumor growth.
Management involves systemic chemotherapy and may include surgical intervention to address compressive effects of the lesion.
Full regimen details, sequencing, and decision criteria are in the structured protocol below.DOI: 10.1210/jc.2010-1692